Cosmos Health Subsidiary Acquires Key Patent, Expands Nanotechnology Manufacturing Investment
COSM•Cosmos Health’s subsidiary Cana Laboratories acquired patent application WO2025108566A1, initiating national and regional filings in key markets to bolster its pharmaceutical, nutraceutical, OTC and specialized healthcare offerings. The firm also expanded nanotechnology investments, leveraging its European GMP-certified manufacturing platform to advance next-generation product development.
1. Patent Acquisition and Filings
Cana Laboratories, a wholly owned subsidiary of Cosmos Health, completed the acquisition of international patent application WO2025108566A1 from Cloudpharm P.C. The subsidiary has launched national and regional patent filings across key international markets to secure rights for advanced pharmaceutical, nutraceutical, OTC and specialized healthcare technologies.
2. Nanotechnology Investment Initiative
In parallel with the patent acquisition, Cana Laboratories announced an expansion of its nanotechnology-based development platforms. The company plans to integrate the newly acquired IP with additional nanotech applications for use in next-generation product formulations across multiple healthcare segments.
3. Strategic Impact on Product Development
The patent supports Cosmos Health’s strategy to enhance its vertical integration and diversify its proprietary product pipeline with high-margin offerings. By combining early-stage discovery methodologies and advanced formulation technologies, the company aims to accelerate commercial launches in the pharmaceutical, nutraceutical and OTC categories.
4. Manufacturing Capabilities and Integration
Cana Laboratories operates a European GMP-certified and EMA-approved manufacturing facility, which will produce nanotechnology-enabled formulations using the acquired IP. This integration of R&D and manufacturing infrastructure is designed to streamline product development and drive scalable revenue growth.
